GlobalData on MSN6d
Eisai and Biogen’s subcutaneous Leqembi set for FDA reviewEisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
In a report released today, Miki Sogi from Bernstein maintained a Buy rating on Astellas Pharma (ALPMF – Research Report), with a price target ...
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...
GlobalData on MSN4d
FDA beats EMA to most approved new drugs in 2024The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...
Biogen CEO Chris Viehbacher targets subcutaneous Leqembi release for Alzheimers treatment Biogens Chris Viehbacher outlines ...
The developer is adding ancillary businesses that support the kind of high-profile companies that have been attracted to the ...
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback